{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:55:27Z","timestamp":1759334127770,"version":"build-2065373602"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fm0208101"],"award-info":[{"award-number":["JP24fm0208101"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trop Med Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne viral disease with a mortality rate of 10\u201330%; however, effective vaccines and therapies for this disease have not yet been developed. Understanding the long-term immune response of recovered individuals is critical for vaccine development and treatment. In this study, we conducted an epidemiological investigation of antibody and memory B cell trends in individuals with SFTS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Peripheral blood mononuclear cells (PBMCs) and plasma were collected from 16 survivors of SFTS and five healthy controls. SFTS virus (SFTSV)-specific humoral immune responses were assessed using enzyme-linked immunosorbent assay (ELISA), biolayer interferometry (BLI), neutralization assays, and flow cytometry.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>SFTSV Gn-specific IgG was detected in plasma samples from all patients using ELISA and BLI. All patient plasma samples also presented neutralizing activity against SFTSV infection, and the IC\u2085\u2080 values were correlated with ELISA OD values (<jats:italic>\u03c1<\/jats:italic>\u2009=\u20090.700, <jats:italic>P<\/jats:italic>\u2009=\u20090.003 and BLI signals (<jats:italic>\u03c1<\/jats:italic>\u2009=\u20090.818, <jats:italic>P<\/jats:italic>\u2009=\u20090.0002). Neutralizing antibodies and SFTSV Gn-specific memory B cells were detected in samples from patients up to 6.7\u00a0years post-infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>SFTSV-specific humoral immunity, including neutralizing antibodies and memory B cells, can persist in the majority of recovered patients, including those as late as 6.7\u00a0years post-infection. This information will be useful for the development of vaccines and antiviral therapies using antibodies against SFTS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41182-025-00807-4","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:53:44Z","timestamp":1759236824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sustained humoral immunity in the patients recovered from severe fever with thrombocytopenia syndrome"],"prefix":"10.1186","volume":"53","author":[{"given":"Ryotaro","family":"Kubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rokusuke","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Takazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koya","family":"Ariyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"4","key":"807_CR1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3201\/eid2604.191011","volume":"26","author":"Y Kobayashi","year":"2020","unstructured":"Kobayashi Y, Kato H, Yamagishi T, Shimada T, Matsui T, Yoshikawa T, et al. Severe fever with thrombocytopenia syndrome, Japan, 2013\u20132017. Emerg Infect Dis. 2020;26(4):692\u20139. https:\/\/doi.org\/10.3201\/eid2604.191011.","journal-title":"Emerg Infect Dis"},{"key":"807_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2021.102501","volume":"67","author":"H Dualis","year":"2021","unstructured":"Dualis H, Zefong AC, Joo LK, Dadar Singh NK, Syed Abdul Rahim SS, Avoi R, et al. Factors and outcomes in Severe Fever with Thrombocytopenia Syndrome (SFTS): a systematic review. Ann Med Surg. 2021;67:102501. https:\/\/doi.org\/10.1016\/j.amsu.2021.102501.","journal-title":"Ann Med Surg"},{"issue":"48","key":"807_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101133","volume":"2","author":"H Cui","year":"2024","unstructured":"Cui H, Shen S, Chen L, Fan Z, Wen Q, Xing Y, et al. Global epidemiology of severe fever with thrombocytopenia syndrome virus in human and animals: a systematic review and meta-analysis. Lancet Reg Health West Pac. 2024;2(48):101133. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101133.","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"807_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41804-7","volume":"14","author":"S Du","year":"2023","unstructured":"Du S, Peng R, Xu W, Qu X, Wang Y, Wang J, et al. Cryo-EM structure of severe fever with thrombocytopenia syndrome virus. Nat Commun. 2023;14(1):6333. https:\/\/doi.org\/10.1038\/s41467-023-41804-7.","journal-title":"Nat Commun"},{"issue":"36","key":"807_CR5","doi-asserted-by":"publisher","first-page":"E7564","DOI":"10.1073\/pnas.1705176114","volume":"114","author":"Y Wu","year":"2017","unstructured":"Wu Y, Zhu Y, Gao F, Jiao Y, Oladejo BO, Chai Y, et al. Structures of phlebovirus glycoprotein Gn and identification of a neutralizing antibody epitope. Proc Natl Acad Sci U S A. 2017;114(36):E7564\u201373. https:\/\/doi.org\/10.1073\/pnas.1705176114.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"807_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51108-z","volume":"15","author":"X Ren","year":"2024","unstructured":"Ren X, Sun J, Kuang W, Yu F, Wang B, Wang Y, et al. A broadly protective antibody targeting glycoprotein Gn inhibits severe fever with thrombocytopenia syndrome virus infection. Nat Commun. 2024;15(1):7009. https:\/\/doi.org\/10.1038\/s41467-024-51108-z.","journal-title":"Nat Commun"},{"issue":"8","key":"807_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/v14081665","volume":"14","author":"M Shimojima","year":"2022","unstructured":"Shimojima M, Sugimoto S, Umekita K, Onodera T, Sano K, Tani H, et al. Neutralizing mAbs against SFTS virus Gn protein show strong therapeutic effects in an SFTS animal model. Viruses. 2022;14(8):1665. https:\/\/doi.org\/10.3390\/v14081665.","journal-title":"Viruses"},{"issue":"2","key":"807_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009103","volume":"15","author":"K Suemori","year":"2021","unstructured":"Suemori K, Saijo M, Yamanaka A, Himeji D, Kawamura M, Haku T, et al. A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome. PLoS Negl Trop Dis. 2021;15(2):e0009103. https:\/\/doi.org\/10.1371\/journal.pntd.0009103.","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"807_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003267","volume":"8","author":"F Ding","year":"2014","unstructured":"Ding F, Guan XH, Kang K, Ding SJ, Huang LY, Xing XS, et al. Risk factors for bunyavirus-associated severe fever with thrombocytopenia syndrome, China. PLoS Negl Trop Dis. 2014;8(10):e3267. https:\/\/doi.org\/10.1371\/journal.pntd.0003267.","journal-title":"PLoS Negl Trop Dis"},{"key":"807_CR10","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.24-0616","author":"S Charoensakulchai","year":"2025","unstructured":"Charoensakulchai S, Matsuno K, Nakayama EE, Shioda T, Imad HA. Epidemiological characteristics of severe fever with thrombocytopenia syndrome. Am J Trop Med Hyg. 2025. https:\/\/doi.org\/10.4269\/ajtmh.24-0616.","journal-title":"Am J Trop Med Hyg"},{"key":"807_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105481","volume":"111","author":"S Zhang","year":"2025","unstructured":"Zhang S, Shang H, Han S, Li J, Peng X, Wu Y, et al. Discovery and characterization of potent broadly neutralizing antibodies from human survivors of severe fever with thrombocytopenia syndrome. EBioMedicine. 2025;111:105481. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105481.","journal-title":"EBioMedicine"},{"key":"807_CR12","unstructured":"National Institute of Infectious Diseases (NIID). Pathogen Detection Manual: Severe Fever with Thrombocytopenia Syndrome. https:\/\/id-info.jihs.go.jp\/relevant\/manual\/010\/SFTS20240502.pdf. Accessed June 11, 2025."},{"issue":"7917","key":"807_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41586-022-04778-y","volume":"607","author":"F Muecksch","year":"2022","unstructured":"Muecksch F, Wang Z, Cho A, Gaebler C, Ben Tanfous T, DaSilva J, et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature. 2022;607(7917):128\u201334. https:\/\/doi.org\/10.1038\/s41586-022-04778-y.","journal-title":"Nature"},{"issue":"11","key":"807_CR14","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.3201\/eid2211.160414","volume":"22","author":"YT Huang","year":"2016","unstructured":"Huang YT, Zhao L, Wen HL, Yang Y, Yu H, Yu XJ. Neutralizing antibodies to severe fever with thrombocytopenia syndrome virus 4 years after hospitalization, China. Emerg Infect Dis. 2016;22(11):1985\u20137. https:\/\/doi.org\/10.3201\/eid2211.160414.","journal-title":"Emerg Infect Dis"},{"key":"807_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijid.2023.05.018","volume":"134","author":"JC Li","year":"2023","unstructured":"Li JC, Ding H, Wang G, Zhang S, Yang X, Wu YX, et al. Dynamics of neutralizing antibodies against severe fever with thrombocytopenia syndrome virus. Int J Infect Dis. 2023;134:95\u20138. https:\/\/doi.org\/10.1016\/j.ijid.2023.05.018.","journal-title":"Int J Infect Dis"},{"issue":"10","key":"807_CR16","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"WS Lee","year":"2020","unstructured":"Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5(10):1185\u201391. https:\/\/doi.org\/10.1038\/s41564-020-00789-5.","journal-title":"Nat Microbiol"},{"key":"807_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.molimm.2022.11.010","volume":"152","author":"S Thomas","year":"2022","unstructured":"Thomas S, Smatti MK, Ouhtit A, Cyprian FS, Almaslamani MA, Thani AA, et al. Antibody-dependent enhancement (ADE) and the role of complement system in disease pathogenesis. Mol Immunol. 2022;152:172\u201382. https:\/\/doi.org\/10.1016\/j.molimm.2022.11.010.","journal-title":"Mol Immunol"},{"issue":"1","key":"807_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40249-022-01017-4","volume":"11","author":"Q Chen","year":"2022","unstructured":"Chen Q, Yang D, Zhang Y, Zhu M, Chen N, Yushan Z. Transmission and mortality risk assessment of severe fever with thrombocytopenia syndrome in China: results from 11-years\u2019 study. Infect Dis Poverty. 2022;11(1):93. https:\/\/doi.org\/10.1186\/s40249-022-01017-4.","journal-title":"Infect Dis Poverty"},{"issue":"1","key":"807_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40249-021-00877-6","volume":"10","author":"SM Lv","year":"2021","unstructured":"Lv SM, Yuan C, Zhang L, Wang YN, Dai ZN, Yang T, et al. Severe fever with thrombocytopenia syndrome with re-infection in China: a case report. Infect Dis Poverty. 2021;10(1):90. https:\/\/doi.org\/10.1186\/s40249-021-00877-6.","journal-title":"Infect Dis Poverty"},{"key":"807_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.744037","volume":"12","author":"L Hu","year":"2021","unstructured":"Hu L, Kong Q, Liu Y, Li J, Bian T, Ma X, et al. Time course of severe fever with thrombocytopenia syndrome virus and antibodies in patients by long-term follow-up study, China. Front Microbiol. 2021;12:744037. https:\/\/doi.org\/10.3389\/fmicb.2021.744037.","journal-title":"Front Microbiol"},{"issue":"10","key":"807_CR21","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1473-3099(18)30293-7","volume":"18","author":"H Li","year":"2018","unstructured":"Li H, Lu QB, Xing B, Zhang SF, Liu K, Du J, et al. Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011\u201317: a prospective observational study. Lancet Infect Dis. 2018;18(10):1127\u201337. https:\/\/doi.org\/10.1016\/S1473-3099(18)30293-7.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"807_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858","volume":"5","author":"C Iannizzi","year":"2023","unstructured":"Iannizzi C, Chai KL, Piechotta V, Valk SJ, Kimber C, Monsef I, et al. Convalescent plasma for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2023;5(5):CD013600. https:\/\/doi.org\/10.1002\/14651858.","journal-title":"Cochrane Database Syst Rev"},{"issue":"25","key":"807_CR23","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMc1602284","volume":"374","author":"TE Fletcher","year":"2016","unstructured":"Fletcher TE, Fischer WA 2nd, Jacob ST. Convalescent plasma for ebola virus disease. N Engl J Med. 2016;374(25):2499\u2013500. https:\/\/doi.org\/10.1056\/NEJMc1602284.","journal-title":"N Engl J Med"},{"key":"807_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.virol.2015.03.010","volume":"482","author":"S Shimada","year":"2015","unstructured":"Shimada S, Posadas-Herrera G, Aoki K, Morita K, Hayasaka D. Therapeutic effect of post-exposure treatment with antiserum on severe fever with thrombocytopenia syndrome (SFTS) in a mouse model of SFTS virus infection. Virology. 2015;482:19\u201327. https:\/\/doi.org\/10.1016\/j.virol.2015.03.010.","journal-title":"Virology"},{"issue":"6","key":"807_CR25","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.4269\/ajtmh.17-0766","volume":"99","author":"S Choi","year":"2018","unstructured":"Choi S, Kim MC, Kwon JS, Kim JY, Lee KH, Kim SH. Case report: use of plasma exchange followed by convalescent plasma therapy in a critically ill patient with severe fever and thrombocytopenia syndrome-associated encephalopathy: cytokine\/chemokine concentrations, viral loads, and antibody responses. Am J Trop Med Hyg. 2018;99(6):1466\u20138. https:\/\/doi.org\/10.4269\/ajtmh.17-0766.","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"807_CR26","doi-asserted-by":"publisher","first-page":"21738","DOI":"10.1038\/s41598-020-78895-x","volume":"10","author":"JV Dzimianski","year":"2020","unstructured":"Dzimianski JV, Lorig-Roach N, O\u2019Rourke SM, Alexander DL, Kimmey JM, DuBois RM. Rapid and sensitive detection of SARS-CoV-2 antibodies by biolayer interferometry. Sci Rep. 2020;10(1):21738. https:\/\/doi.org\/10.1038\/s41598-020-78895-x.","journal-title":"Sci Rep"},{"issue":"4","key":"807_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250085","volume":"53","author":"L Reusch","year":"2023","unstructured":"Reusch L, Angeletti D. Memory b-cell diversity: from early generation to tissue residency and reactivation. Eur J Immunol. 2023;53(4):2250085. https:\/\/doi.org\/10.1002\/eji.202250085.","journal-title":"Eur J Immunol"},{"issue":"3","key":"807_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","volume":"384","author":"DM Weinreich","year":"2021","unstructured":"Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2035002.","journal-title":"N Engl J Med"},{"key":"807_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1083429","volume":"14","author":"E Taki","year":"2023","unstructured":"Taki E, Ghanavati R, Navidifar T, Dashtbin S, Heidary M, Moghadamnia M. Ebanga\u2122: the most recent FDA-approved drug for treating Ebola. Front Pharmacol. 2023;14:1083429. https:\/\/doi.org\/10.3389\/fphar.2023.1083429.","journal-title":"Front Pharmacol"},{"issue":"2","key":"807_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007375","volume":"15","author":"KH Kim","year":"2019","unstructured":"Kim KH, Kim J, Ko M, Chun JY, Kim H, Kim S, et al. An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus. PLoS Pathog. 2019;15(2):e1007375. https:\/\/doi.org\/10.1371\/journal.ppat.1007375.","journal-title":"PLoS Pathog"},{"issue":"1","key":"807_CR31","doi-asserted-by":"publisher","first-page":"e00061","DOI":"10.1128\/mSphere.00061-15","volume":"1","author":"H Tani","year":"2016","unstructured":"Tani H, Fukuma A, Fukushi S, Taniguchi S, Yoshikawa T, Iwata-Yoshikawa N, et al. Efficacy of T-705 (Favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus. mSphere. 2016;1(1):e00061-e115. https:\/\/doi.org\/10.1128\/mSphere.00061-15.","journal-title":"mSphere."},{"issue":"10","key":"807_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206416","volume":"13","author":"H Tani","year":"2018","unstructured":"Tani H, Komeno T, Fukuma A, Fukushi S, Taniguchi S, Shimojima M, et al. Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: dose-efficacy studies upon oral administration. PLoS ONE. 2018;13(10):e0206416. https:\/\/doi.org\/10.1371\/journal.pone.0206416.","journal-title":"PLoS ONE"},{"issue":"1","key":"807_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01901-w","volume":"8","author":"E Hammarlund","year":"2017","unstructured":"Hammarlund E, Thomas A, Amanna IJ, Holden LA, Slayden OD, Park B, et al. Plasma cell survival in the absence of B cell memory. Nat Commun. 2017;8(1):1781. https:\/\/doi.org\/10.1038\/s41467-017-01901-w.","journal-title":"Nat Commun"},{"issue":"12","key":"807_CR34","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1073\/pnas.0800555105","volume":"105","author":"A Ahuja","year":"2008","unstructured":"Ahuja A, Anderson SM, Khalil A, Shlomchik MJ. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci U S A. 2008;105(12):4802\u20137. https:\/\/doi.org\/10.1073\/pnas.0800555105.","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Tropical Medicine and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41182-025-00807-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41182-025-00807-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41182-025-00807-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:53:45Z","timestamp":1759236825000},"score":1,"resource":{"primary":{"URL":"https:\/\/tropmedhealth.biomedcentral.com\/articles\/10.1186\/s41182-025-00807-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["807"],"URL":"https:\/\/doi.org\/10.1186\/s41182-025-00807-4","relation":{},"ISSN":["1349-4147"],"issn-type":[{"type":"electronic","value":"1349-4147"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol was reviewed and approved by the ethics committee of Nagasaki University Hospital (approval no. 25042404). Sixteen patients and five healthy donors with no history of SFTS were included, and residual samples obtained from a previous study were used (Approval No. 24060601-2). Patients were recruited from two hospitals in Nagasaki Prefecture. Owing to the retrospective and non-interventional nature of the study, informed consent was obtained using an opt-out approach in accordance with ethical guidelines. Information regarding the study was disclosed on the websites of participating institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"127"}}